Alnylam Pharmaceuticals, Inc. announced sales results for the fourth quarter and full year 2021. For the quarter, Company reported Preliminary global net product revenues of approximately $139 million, representing quarterly growth of 15% compared to third quarter of 2021.

For the year, company reported Preliminary global net product revenues of $475 million, representing annual growth of 55% compared to full year 2020.